Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | CRHBP | P24387 | 1/20 | 0.50 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.50 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.50 |
| ▸ | CDC7 | O00311 | 8/20 | 0.47 |
| ▸ | DBF4 | Q9UBU7 | 8/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26659237 | 0.83 | LMNA (0.71) | KDM4EALDH1A1HPGDLMNAMAPT | |
| SCHEMBL5641718 | 0.83 | CDC7 (0.68) | KDM4EALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL26795701 | 0.82 | P2RX7 (0.42) | KDM4EALDH1A1HPGDLMNAMEN1 | |
| SCHEMBL17291419 | 0.82 | CDC7 (0.70) | KDM4EMEN1MAPTKMT2AHSP90AA1 | |
| SCHEMBL290342 | 0.81 | CDC7 (0.72) | KDM4EALDH1A1HPGDLMNAMEN1 | |
| SCHEMBL10821105 | 0.80 | ALDH1A1 (0.52) | KDM4EALDH1A1HPGDLMNAMEN1 | |
| SCHEMBL299676 | 0.80 | KDM4E (0.72) | KDM4EALDH1A1HPGDLMNAMEN1 | |
| SCHEMBL5640705 | 0.80 | CDC7 (0.56) | KDM4EALDH1A1LMNAMEN1MAPT | |
| SCHEMBL3664702 | 0.80 | P2RX7 (0.46) | KDM4EALDH1A1HPGDLMNAMEN1 | |
| SCHEMBL8341363 | 0.80 | MAPT (0.78) | KDM4EALDH1A1MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133204-B2 | 5-membered heterocyclic amides and related compounds | H. LUNDBECK A/S (DK) | 2015-09-15 | — | — | US | disclosed |
| US-9133204-B2 | 5-membered heterocyclic amides and related compounds | H. LUNDBECK A/S (DK) | 2015-09-15 | — | — | US | disclosed |
| US-9133204-B2 | 5-membered heterocyclic amides and related compounds | H. LUNDBECK A/S (DK) | 2015-09-15 | — | — | US | disclosed |
| EP-2178865-B1 | 5-MEMBERED HETEROCYCLIC AMIDES AND RELATED COMPOUNDS | LUNDBECK H AS (DK) | 2015-08-19 | — | — | EP | disclosed |
| EP-2178865-B1 | 5-MEMBERED HETEROCYCLIC AMIDES AND RELATED COMPOUNDS | LUNDBECK H AS (DK) | 2015-08-19 | — | — | EP | disclosed |
| US-20150005293-A1 | 5-Membered Heterocyclic Amides And Related Compounds | MINDIMMUNE THERAPEUTICS, INC. | 2015-01-01 | — | — | US | disclosed |
| US-20150005293-A1 | 5-Membered Heterocyclic Amides And Related Compounds | MINDIMMUNE THERAPEUTICS, INC. | 2015-01-01 | — | — | US | disclosed |
| US-20150005293-A1 | 5-Membered Heterocyclic Amides And Related Compounds | MINDIMMUNE THERAPEUTICS, INC. | 2015-01-01 | — | — | US | disclosed |
| US-20100292236-A1 | 5-Membered Heterocyclic Amides And Related Compounds | H. LUNDBECK A/S (DK) | 2010-11-18 | — | — | US | disclosed |
| US-20100292236-A1 | 5-Membered Heterocyclic Amides And Related Compounds | H. LUNDBECK A/S (DK) | 2010-11-18 | — | — | US | disclosed |
| EP-2178865-A2 | 5-MEMBERED HETEROCYCLIC AMIDES AND RELATED COMPOUNDS | Lundbeck, H., A/S (DK) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009012482-A2 | 5-MEMBERED HETEROCYCLIC AMIDES AND RELATED COMPOUNDS | H.LUNDBECK A/S (DK) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009012482-A2 | 5-MEMBERED HETEROCYCLIC AMIDES AND RELATED COMPOUNDS | H.LUNDBECK A/S (DK) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005293-A1 | 5-Membered Heterocyclic Amides And Related Compounds | GPR35, HCAR2, HCAR1 | KDM4E 3311/4885ALDH1A1 875/4885HPGD 388/4885 |
| US-20100292236-A1 | 5-Membered Heterocyclic Amides And Related Compounds | GPR35, HCAR2, HCAR1 | KDM4E 3311/4885ALDH1A1 875/4885HPGD 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.